Onco-Innovations' Inka Health to Launch Global AI-Oncology Consortium to Advance Predictive Cancer Research

Rhea-AI Summary

Onco-Innovations' subsidiary Inka Health is launching a global AI-oncology consortium called Predicting Oncology Outcomes using Multimodal AI (PROmAI). The initiative aims to unite pharmaceutical companies, academic institutions, and data science experts to advance predictive modeling in cancer research. PROmAI will focus on developing AI approaches that integrate real-world and clinical trial data from multiple sources to enhance predictive accuracy and regulatory relevance in translational oncology. The consortium seeks to establish standards for AI transparency and trustworthiness in medical research while accelerating progress toward personalized cancer care. The initiative is currently in its formative phase, with discussions ongoing with potential founding members.

VANCOUVER, BC / ACCESS Newswire / June 5, 2025 / Onco-Innovations Limited (CBOE:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), is launching a new strategic initiative to establish a global consortium dedicated to advancing the use of artificial intelligence (AI) in oncology. This foundational step, the Company believes, has the potential to shape a new era of collaboration at the intersection of AI and cancer research, where breakthroughs in data science can directly inform therapeutic discovery and clinical translation.

The initiative, to be led by Inka Health, aims to bring together leading pharmaceutical companies, academic institutions, and data science experts to form a pre-competitive collaboration focused on improving predictive modeling in cancer research and development. The initiative, to be named Predicting Oncology Outcomes using Multimodal AI (PROmAI), is designed to serve as a platform for high-impact, multi-stakeholder innovation in clinically-relevant AI. By fostering early alignment among scientific, clinical, and industry leaders, PROmAI seeks to overcome long-standing silos that have limited the translational utility of AI in oncology.

The PROmAI Consortium will focus on developing and validating next-generation AI approaches that integrate real-world and clinical trial data-spanning molecular, imaging, clinical, and other multimodal sources. These methodologies will aim to enhance the predictive accuracy, interpretability, transportability, and regulatory relevance of AI in translational oncology. In the Company's view, such an approach is especially critical in oncology, where heterogeneity across patient populations and data types continues to challenge conventional modeling techniques.

By creating a trusted environment for cross-sector research, the consortium seeks to accelerate progress toward more personalized, cost-effective, and outcomes-driven cancer care. It is also intended to provide a framework for contributing to evolving standards around AI transparency, utility, and trustworthiness in medical research. In doing so, PROmAI intends to help define what credible, reproducible, and ethically grounded AI should look like in a clinical drug development context.

PROmAI represents a strategic milestone in the Company's innovation mission, which includes leading the development of AI-driven solutions that meaningfully improve patient outcomes and streamline the oncology drug development lifecycle. It also marks a bold step toward establishing Inka Health as a central convenor of cross-disciplinary innovation in one of medicine's most complex and high-stakes domains.

"Pursuing this initiative reflects our belief that the next generation of AI in medicine won't be defined by algorithms alone, but by how well we embed those algorithms into the real-world complexities of drug development and patient care. PROmAI is a natural evolution of Inka Health's mission to lead in clinically credible, scientifically grounded AI innovation. By creating a collaborative framework from the outset, we hope to be at the forefront of not only building better models - but also in shaping how AI can responsibly and reliably influence oncology research at scale," stated Paul Arora, Co-Founder of Inka Health.

The initiative is currently in its formative phase, with formal discussions underway with prospective founding members. Additional announcements will be made as key participants confirm their involvement and collaborative plans move forward.

About Inka Health

Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data - including genomics, transcriptomics, and proteomics - SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health helps pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the proposed initiative and in relation to the further development, potential commercialization and benefits of the Company's technologies and expertise, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further pursue the initiative described herein, or to further develop, prove out or commercialize the Company's technologies, as well as the failure to receive regulatory approval in respect of the Company's technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

What is the PROmAI consortium announced by Onco-Innovations (ONNVF)?

PROmAI (Predicting Oncology Outcomes using Multimodal AI) is a global consortium launched by Inka Health to advance AI use in oncology research by combining real-world and clinical trial data from multiple sources.

How will PROmAI impact cancer research and development?

PROmAI aims to enhance predictive modeling in cancer research by developing AI approaches that improve accuracy, interpretability, and regulatory relevance in translational oncology through cross-sector collaboration.

Who are the participants in Onco-Innovations' PROmAI consortium?

The consortium is currently in its formative phase, with plans to include pharmaceutical companies, academic institutions, and data science experts. Formal discussions are underway with prospective founding members.

What are the main objectives of the PROmAI initiative by ONNVF?

PROmAI aims to accelerate progress toward personalized cancer care, establish AI standards in medical research, and create a framework for credible, reproducible, and ethical AI in clinical drug development.

How does PROmAI plan to address current challenges in oncology research?

PROmAI will focus on overcoming challenges related to patient population heterogeneity and diverse data types by developing integrated AI approaches that combine molecular, imaging, clinical, and other multimodal sources.